Compare UMH & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UMH | FTRE |
|---|---|---|
| Founded | 1968 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 1995 | 2023 |
| Metric | UMH | FTRE |
|---|---|---|
| Price | $16.08 | $18.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $17.75 | $14.06 |
| AVG Volume (30 Days) | 753.2K | ★ 1.2M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.84% | N/A |
| EPS Growth | ★ 133.33 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | $261,754,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | $5.51 | N/A |
| Revenue Next Year | $2.51 | $3.09 |
| P/E Ratio | $200.75 | ★ N/A |
| Revenue Growth | ★ 8.81 | 1.00 |
| 52 Week Low | $13.93 | $8.31 |
| 52 Week High | $16.77 | $21.39 |
| Indicator | UMH | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 48.21 | 53.83 |
| Support Level | $14.81 | $16.45 |
| Resistance Level | $16.28 | $19.34 |
| Average True Range (ATR) | 0.27 | 0.76 |
| MACD | -0.08 | -0.00 |
| Stochastic Oscillator | 6.62 | 74.66 |
UMH Properties Inc together with its subsidiaries, is a real estate investment trust. It is engaged in the business of ownership and operation of manufactured home communities - leasing manufactured homesites to residents. The Company also leases manufactured homes to residents and, through its wholly-owned taxable REIT subsidiary, it sells and finances the sale of manufactured homes to residents and prospective residents of its communities and for placement on customers' privately-owned land. The company also owns the land, utility connections, streets, lighting, driveways, common area amenities, and other capital improvements. It earns income from lease agreements for its sites and homes, where the company is the lessor.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.